2025-06-30 アメリカ国立衛生研究所 (NIH)
<関連情報>
- https://www.nih.gov/news-events/news-releases/breast-cancer-risk-younger-women-may-be-influenced-hormone-therapy
- https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00211-6/abstract
ホルモン療法の使用と若年発症乳癌:閉経前乳癌共同研究グループに含まれる前向きコホートのプール解析 Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
Katie M O’Brien, PhD ∙ Melissa G House, MS ∙ Mandy Goldberg, PhD ∙ Michael E Jones, PhD ∙ Clarice R Weinberg, PhD ∙ Amy Berrington de Gonzalez, DPhil ∙ et al.
The Lancet Oncology Published: July 2025
DOI:https://doi.org/10.1016/S1470-2045(25)00211-6
Summary
Background
Oestrogen plus progestin hormone therapy is an established risk factor for breast cancer in postmenopausal women. We examined the less well-studied association between exogenous hormones and breast cancer in young women, who might use hormone therapy after gynaecological surgery or to relieve perimenopausal symptoms.
Methods
In this pooled cohort analysis, we investigated the relationship between exogenous hormones and breast cancer in young women using data from 10–13 prospective cohorts from North America, Europe, Asia, and Australia. The participating cohorts followed up women for incident breast cancer until age 55 years. We used cohort-stratified, multivariable-adjusted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CI for associations of hormone therapy with incident young-onset breast cancer. We also estimated risk differences based on cumulative risk until age 55 years.
Findings
We included 459 476 women aged 16–54 years (mean 42·0 years [IQR 35·5–49·2]), of whom 8455 (2%) developed young-onset breast cancer (diagnosed before age 55 years; median follow-up 7·8 years [5·2–11·2]). Overall, 15% of participants reported using hormone therapy, with oestrogen plus progestin hormone therapy (6%) and unopposed oestrogen (5%) being the most common types. Cumulative risk of young-onset breast cancer was 4·1% in non-users. Hormone therapy of any type was not associated with incident young-onset breast cancer (HR 0·96 [95% CI 0·88 to 1·04]), but ever oestrogen hormone therapy use was inversely associated (0·86 [0·75 to 0·98]; risk difference –0·5% [–1·0 to –0·0]). The HR for ever oestrogen plus progestin hormone therapy and young-onset breast cancer was 1·10 (0·98 to 1·24), with positive associations observed for long-term use (1·18 [1·01 to 1·38] for >2 years) and use among women without hysterectomy or bilateral oophorectomy (1·15 [1·02 to 1·31]). Oestrogen hormone therapy and young-onset breast cancer association was similar for all breast cancer subtypes, but oestrogen plus progestin hormone therapy was more strongly associated with oestrogen receptor negative (1·44 [1·11 to 1·88]) and triple-negative disease (1·50 [1·02 to 2·20]) than with other subtypes.
Interpretation
Oestrogen hormone therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin hormone therapy was associated with higher young-onset breast cancer incidence among women with intact uterus and ovaries. These findings largely parallel results from studies of hormone use and later-onset breast cancer and provide novel evidence for establishing clinical recommendations among younger women.
Funding
NIH Intramural Research Program.
